Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Callery

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
British Journal of Clinical Pharmacology|October 6, 2025
Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malariaJunjie Ding, Richard M Hoglund, Rob W van der Pluijm, et al.
Malaria Journal|January 3, 2024
Expanding the roles of community health workers to sustain programmes during malaria elimination: a meeting report on operational research in Southeast AsiaLek Dysoley, James J Callery, Voeurng Bunreth, et al.
Antimicrobial Agents and Chemotherapy|February 17, 2026
Changing genetic profiles of <i>Plasmodium falciparum</i> piperaquine resistance in Southeast Asia over 25 yearsSuttipat Srisutham, Kanokon Suwannasin, Aungkana Saejeng, et al.
Antimicrobial Agents and Chemotherapy|September 13, 2021
Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong SubregionMallika Imwong, Kanokon Suwannasin, Suttipat Srisutham, et al.
Elife|February 21, 2023
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)William H K Schilling, Podjanee Jittamala, James A Watson, et al.
BMC Infectious Diseases|January 15, 2024
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trialViravarn Luvira, William H K Schilling, Podjanee Jittamala, et al.
The Lancet. Infectious Diseases|March 11, 2022
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trialThomas J Peto, Rupam Tripura, James J Callery, et al.
The Lancet. Infectious Diseases|October 1, 2023
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trialWilliam H K Schilling, Podjanee Jittamala, James A Watson, et al.
Malaria Journal|April 13, 2022
Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learningDebashish Das, Ranitha Vongpromek, Thanawat Assawariyathipat, et al.
The Journal of Infectious Diseases|July 20, 2023
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)Podjanee Jittamala, William H K Schilling, James A Watson, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
British Journal of Clinical Pharmacology|October 6, 2025
Population pharmacokinetics of artemether-lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malariaJunjie Ding, Richard M Hoglund, Rob W van der Pluijm, et al.
Malaria Journal|January 3, 2024
Expanding the roles of community health workers to sustain programmes during malaria elimination: a meeting report on operational research in Southeast AsiaLek Dysoley, James J Callery, Voeurng Bunreth, et al.
Antimicrobial Agents and Chemotherapy|February 17, 2026
Changing genetic profiles of <i>Plasmodium falciparum</i> piperaquine resistance in Southeast Asia over 25 yearsSuttipat Srisutham, Kanokon Suwannasin, Aungkana Saejeng, et al.
Antimicrobial Agents and Chemotherapy|September 13, 2021
Evolution of Multidrug Resistance in Plasmodium falciparum: a Longitudinal Study of Genetic Resistance Markers in the Greater Mekong SubregionMallika Imwong, Kanokon Suwannasin, Suttipat Srisutham, et al.
Elife|February 21, 2023
Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)William H K Schilling, Podjanee Jittamala, James A Watson, et al.
BMC Infectious Diseases|January 15, 2024
Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trialViravarn Luvira, William H K Schilling, Podjanee Jittamala, et al.
The Lancet. Infectious Diseases|March 11, 2022
Triple therapy with artemether-lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trialThomas J Peto, Rupam Tripura, James J Callery, et al.
The Lancet. Infectious Diseases|October 1, 2023
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trialWilliam H K Schilling, Podjanee Jittamala, James A Watson, et al.
Malaria Journal|April 13, 2022
Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learningDebashish Das, Ranitha Vongpromek, Thanawat Assawariyathipat, et al.
The Journal of Infectious Diseases|July 20, 2023
Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)Podjanee Jittamala, William H K Schilling, James A Watson, et al.
Pageof 5